Recommendation ID
NICE recommends that a study is conducted to generate robust evidence about the benefits of roflumilast as an add-on to LAMA plus LABA/ICS or LAMA plus LABA for those people who are intolerant to ICS.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Roflumilast for the management of severe chronic obstructive pulmonary disease
Date issued
January 2012

Other details

Is this a recommendation for the use of a technology only in the context of research? Yes  
Is it a recommendation that suggests collection of data or the establishment of a register?   No